UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
May 2017
Commission File Number: 001-38067
Verona Pharma plc
(Exact Name of Registrant as Specified in Its Charter)
3 More London Riverside
London SE1 2RE UK
+44 203 283 4200
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On May 25, 2017, Verona Pharma plc (the “Company”) issued a release notification system announcement in the United Kingdom (the “RNS”) disclosing the exercise by the underwriters of its global offering of American Depositary Shares and ordinary shares of their over-allotment option to purchase additional American Depositary Shares of the Company
The RNS is furnished herewith as Exhibit 99.1 to this Report on Form 6-K.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| VERONA PHARMA PLC |
| | |
| | |
Date: May 26, 2017 | | By: | /s/ Jan-Anders Karlsson |
| | | Name: | Jan-Anders Karlsson, Ph.D. |
| | | Title: | Chief Executive Officer |
3
EXHIBIT INDEX
Exhibit
No. | | Description |
| | |
99.1 | | Release Notification System Announcement of Verona Pharma plc, dated May 25, 2017 |
4
